Naveen Kumar

fda meddra ctd harmonisation ich para iv filings market exlusivities 180 day exclusivity loopholes of hatch waxman act reverse payment agreements authorized generics hatch waxman act india indian pharma patent cliff m&a abbott-piramal deal mergers and acquisitions food and drug administration drug approvals 2011 vaccine drugs and medications